DGX Quest Diagnostics Incorporated

Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Date	Price Target	Rating	Analyst
4/2/2025	$195.00	Buy	Redburn Atlantic
3/4/2025	$185.00	Buy → Neutral	Citigroup
1/6/2025	$169.00 → $174.00	Market Perform → Outperform	Leerink Partners
12/17/2024	$145.00 → $172.00	Equal-Weight → Overweight	Morgan Stanley
12/10/2024	$175.00 → $185.00	Buy	Jefferies
10/23/2024	$157.00 → $182.00	Neutral → Outperform	Robert W. Baird
8/28/2024	$165.00	In-line	Evercore ISI
7/10/2024	$145.00 → $165.00	Neutral → Buy	Citigroup
2/26/2024	$135.00	Market Perform	Leerink Partners
2/7/2024	$140.00 → $155.00	Hold → Buy	Jefferies

Quest Diagnostics Incorporated

Peers

Recent Analyst Ratings for Quest Diagnostics Incorporated

Quest Diagnostics Incorporated Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Carter Robert B was granted 1,203 shares, increasing direct ownership by 81% to 2,685 units (SEC Form 4)

Director Diaz Luis was granted 1,203 shares, increasing direct ownership by 42% to 4,054 units (SEC Form 4)

Director Gregg Vicky B was granted 1,203 shares, increasing direct ownership by 7% to 18,138 units (SEC Form 4)

Director Doi Tracey was granted 1,203 shares, increasing direct ownership by 23% to 6,490 units (SEC Form 4)

Director Main Timothy L was granted 1,203 shares, increasing direct ownership by 5% to 26,297 units (SEC Form 4)

Director Morrison Denise M was granted 1,203 shares, increasing direct ownership by 13% to 10,742 units (SEC Form 4)

Director Lassiter Wright Iii was granted 1,203 shares, increasing direct ownership by 15% to 9,037 units (SEC Form 4)

Director Ring Timothy M was granted 1,203 shares, increasing direct ownership by 4% to 29,507 units (SEC Form 4)

Director Pfeiffer Gary M was granted 1,203 shares, increasing direct ownership by 4% to 30,669 units (SEC Form 4)

SVP & Chief Commercial Officer Delaney Mark E sold $306,800 worth of shares (1,748 units at $175.51), decreasing direct ownership by 19% to 7,498 units (SEC Form 4)